Dylan Gagler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dylan Gagler has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Blaney
NYU Langone’s Laura and Isaac Perlmutter Cancer Center 3 New York, NY
186 shared publications - Eileen Mary Boyle
Myeloma Research Program, NYU Langone, Perlmutter Cancer Center
185 shared publications - Faith E. Davies
Perlmutter Cancer Center, NYU Langone Health, New York, NY
185 shared publications - Francesco Maura
Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
185 shared publications - Gareth John Morgan
Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
185 shared publications - Ola Landgren
Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA
185 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Bioinformatic pipeline details
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Bioinformatic pipeline details
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S10 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Supplementary Figure 1. Overview of bioinformatic workflow for each module of the Myeloma Genome Pipeline 1000 (MGP1000). Supplementary Figure 2. Bar plot highlighting the cases where the self-identified race did not match the ancestry. Supplementary Figure 3. Comparison of copy number variation (CNV) and single nucleotide variants (SNV) between African-dominant (AFR) and European-dominant (EUR) admixture clusters. Supplementary Figure 4. Comparison of tumor coverage and purity stratified by admixture cluster assignment. Supplementary Figure 5. Comparison of age and total mutational burden (TMB) stratified by admixture cluster assignment. Supplementary Figure 6. The number of kataegis foci are associated with admixture groups. Supplementary Figure 7. Principal component analysis (PCA) plots generated via EIGENSTRAT for the AFR Dominant population. Supplementary Figure 8. Haplotype distribution at each of 6 significantly distributed SNPs from those comprising the PRS. Supplementary Figure 9. Relationship between polygenic risk score (PRS), APOBEC activity and APOBEC SNP genotypes. Supplementary Figure 10. APOBEC (SBS2/SBS13) contribution by Admixture group and pre/post-gain stage.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S10 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Supplementary Figure 1. Overview of bioinformatic workflow for each module of the Myeloma Genome Pipeline 1000 (MGP1000). Supplementary Figure 2. Bar plot highlighting the cases where the self-identified race did not match the ancestry. Supplementary Figure 3. Comparison of copy number variation (CNV) and single nucleotide variants (SNV) between African-dominant (AFR) and European-dominant (EUR) admixture clusters. Supplementary Figure 4. Comparison of tumor coverage and purity stratified by admixture cluster assignment. Supplementary Figure 5. Comparison of age and total mutational burden (TMB) stratified by admixture cluster assignment. Supplementary Figure 6. The number of kataegis foci are associated with admixture groups. Supplementary Figure 7. Principal component analysis (PCA) plots generated via EIGENSTRAT for the AFR Dominant population. Supplementary Figure 8. Haplotype distribution at each of 6 significantly distributed SNPs from those comprising the PRS. Supplementary Figure 9. Relationship between polygenic risk score (PRS), APOBEC activity and APOBEC SNP genotypes. Supplementary Figure 10. APOBEC (SBS2/SBS13) contribution by Admixture group and pre/post-gain stage.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S10 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Supplementary Table 1. Summary of the source of data included in this study. Supplementary Table 2. Summary of demographic and genomic metadata variables collected for patients included in this study. Supplementary Table 3. Comparison of genomic classification events (n = 130) between EUR and AFR Dominant populations in NDMM patients with high ancestry contribution (EUR >0.8 or AFR >0.8). Supplementary Table 4. Comparison of genomic classification events (n = 130) using AFR ancestry as a linear value (linear regression model). Supplementary Table 5. Comparison of genomic classification events (n = 130) between EUR and AFR dominant populations in NDMM patients with high tumor purity (> 0.5) and high coverage (> 40x). Supplementary Table 6. Comparison of genomic classification events between the P1000 EUR group and the GMMG-HD6 cohort. Supplementary Table 7. Odds-ratio comparison for risk of developing multiple myeloma or myeloma precursor conditions for 31 germline SNPs. Supplementary Table 8. Proportion of germline SNPs in APOBEC across AFR and EUR in NDMM. Supplementary Table 9. Subanalysis for comparison of association of APOBEC mutational signatures (SBS2/SBS13) with 31 germline SNPs based on ancestry cluster (EUR, AFR). Supplementary Table 10. The age of multiple myeloma diagnosis from the SEER database.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S10 from Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Supplementary Table 1. Summary of the source of data included in this study. Supplementary Table 2. Summary of demographic and genomic metadata variables collected for patients included in this study. Supplementary Table 3. Comparison of genomic classification events (n = 130) between EUR and AFR Dominant populations in NDMM patients with high ancestry contribution (EUR >0.8 or AFR >0.8). Supplementary Table 4. Comparison of genomic classification events (n = 130) using AFR ancestry as a linear value (linear regression model). Supplementary Table 5. Comparison of genomic classification events (n = 130) between EUR and AFR dominant populations in NDMM patients with high tumor purity (> 0.5) and high coverage (> 40x). Supplementary Table 6. Comparison of genomic classification events between the P1000 EUR group and the GMMG-HD6 cohort. Supplementary Table 7. Odds-ratio comparison for risk of developing multiple myeloma or myeloma precursor conditions for 31 germline SNPs. Supplementary Table 8. Proportion of germline SNPs in APOBEC across AFR and EUR in NDMM. Supplementary Table 9. Subanalysis for comparison of association of APOBEC mutational signatures (SBS2/SBS13) with 31 germline SNPs based on ancestry cluster (EUR, AFR). Supplementary Table 10. The age of multiple myeloma diagnosis from the SEER database.
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (5) , 742-758
Genomic features do not account for differences in multiple myeloma risk by ancestry
Studies have reported conflicting findings regarding the contribution of germline variants or somatic genomic drivers to racial disparities in multiple myeloma (MM). To comprehensively investigate somatic drivers in relation to inherited genetics in MM, we combined newly sequenced whole-genome sequencing data with publicly available datasets (total n = 1,286). Overall, we did not identify germline or somatic genomic differences that explain the different risk of developing MM between patients with genetic similarity to African (AFR) or European (EUR) reference populations. A difference in the detectability and timing of APOBEC-associated and germinal center mutational activity was observed. Integrating epidemiological data and mutational signature-based temporal estimates, we challenge the assumption that individuals in the AFR group develop MM at a younger age. Finally, we demonstrate that, with equal access to efficacious therapies, patients in the AFR and EUR groups have equivalent clinical outcomes.
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (5) , 742-758
Genomic features do not account for differences in multiple myeloma risk by ancestry
Studies have reported conflicting findings regarding the contribution of germline variants or somatic genomic drivers to racial disparities in multiple myeloma (MM). To comprehensively investigate somatic drivers in relation to inherited genetics in MM, we combined newly sequenced whole-genome sequencing data with publicly available datasets (total n = 1,286). Overall, we did not identify germline or somatic genomic differences that explain the different risk of developing MM between patients with genetic similarity to African (AFR) or European (EUR) reference populations. A difference in the detectability and timing of APOBEC-associated and germinal center mutational activity was observed. Integrating epidemiological data and mutational signature-based temporal estimates, we challenge the assumption that individuals in the AFR group develop MM at a younger age. Finally, we demonstrate that, with equal access to efficacious therapies, patients in the AFR and EUR groups have equivalent clinical outcomes.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S16 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Methylation probe intensity across chromosome 1. Heatmap representation of the beta value for all probes across chromosome 1, the probes a presented in a genomic coordinate sorted fashion. The recurrent regions of deletion, gain, templated insertion, and chromothripsis have be highlighted along with the cytoband information for reference.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S16 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Methylation probe intensity across chromosome 1. Heatmap representation of the beta value for all probes across chromosome 1, the probes a presented in a genomic coordinate sorted fashion. The recurrent regions of deletion, gain, templated insertion, and chromothripsis have be highlighted along with the cytoband information for reference.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Spreadsheet S10 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Common dependency pathway analysis
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Spreadsheet S10 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Common dependency pathway analysis
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Recurrent regions of copy number gain and loss together with the candidate genes located within the regions.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Recurrent regions of copy number gain and loss together with the candidate genes located within the regions.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Genes with increased dependency in cell lines with del(1p) [part A] Genes with increased dependency in cell lines with del(1p) [part B]
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Genes with increased dependency in cell lines with del(1p) [part A] Genes with increased dependency in cell lines with del(1p) [part B]
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Recurrent regions of chromothripsis and chromoplexy together with the candidate genes located within the regions. A. CHromothripsis B. Templated Instertion
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Recurrent regions of chromothripsis and chromoplexy together with the candidate genes located within the regions. A. CHromothripsis B. Templated Instertion